RBC Capital Maintains Underperform on Amrize, Lowers Price Target to $32

Benzinga Newsdesk www.benzinga.com Negative 95.9%

Neg 95.9% Neu 0% Pos 0%

RBC Capital analyst Anthony Codling maintains Amrize (NYSE:AMRZ) with a Underperform and lowers the price target from $48 to $32.